Free Trial

Genus (LON:GNS) Shares Pass Above 200 Day Moving Average - Should You Sell?

Genus logo with Medical background

Key Points

  • Genus plc's share price exceeded its 200-day moving average of GBX 2,198.58, reaching GBX 2,650.21 during recent trading.
  • Analysts have a consensus buy rating for Genus, with a target price upgraded to GBX 2,900 by multiple brokerages.
  • The company's recent quarterly earnings report showed earnings per share of GBX 81.80, with analysts predicting GBX 70.96 for the current fiscal year.
  • MarketBeat previews top five stocks to own in November.

Genus plc (LON:GNS - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 2,198.58 ($29.32) and traded as high as GBX 2,665 ($35.54). Genus shares last traded at GBX 2,650.21 ($35.35), with a volume of 246,355 shares changing hands.

Analyst Ratings Changes

A number of brokerages have weighed in on GNS. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Genus from GBX 2,550 to GBX 2,900 and gave the stock a "buy" rating in a research note on Monday, September 15th. Shore Capital restated a "buy" rating and issued a GBX 2,900 price objective on shares of Genus in a research report on Thursday, September 4th. Two analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of GBX 2,900.

View Our Latest Report on GNS

Genus Stock Performance

The company has a debt-to-equity ratio of 53.12, a current ratio of 1.80 and a quick ratio of 1.08. The firm has a market capitalization of £1.75 billion, a P/E ratio of 9,152.25, a P/E/G ratio of 2.87 and a beta of 0.37. The stock's 50 day moving average is GBX 2,550.26 and its two-hundred day moving average is GBX 2,198.58.

Genus (LON:GNS - Get Free Report) last posted its quarterly earnings results on Thursday, September 4th. The company reported GBX 81.80 earnings per share for the quarter. Genus had a net margin of 1.18% and a return on equity of 1.41%. As a group, equities analysts anticipate that Genus plc will post 70.9644323 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Jorgen Kokke sold 3,450 shares of the company's stock in a transaction dated Thursday, September 25th. The stock was sold at an average price of GBX 2,332, for a total value of £80,454. Corporate insiders own 0.70% of the company's stock.

Genus Company Profile

(Get Free Report)

Genus plc operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Genus Research and Development. It sells breeding pigs and semen to breed pigs with various characteristics for pork production under the PIC brand.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Genus Right Now?

Before you consider Genus, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genus wasn't on the list.

While Genus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.